Atrasentan is mainly used for the long-term treatment and management of which types of kidney diseases

Atrasentan (Atrasentan) is a selective endothelin receptor antagonist, mainly used for the long-term treatment and management of diabetic nephropathy (Diabetic Nephropathy, DN). Diabetic nephropathy is one of the common and serious complications in patients with diabetes, manifested by increased proteinuria, gradual decline in renal function, and may eventually develop into end-stage renal disease. Atrasentan improves renal hemodynamics and reduces proteinuria by blocking endothelin receptors, thereby delaying the progression of the disease.

In clinical studies, atrasentan has shown significant renal protection. Its mechanism of action is mainly to inhibit the binding of endothelin-1 (ET-1) to its receptors, relieve vasoconstriction and inflammatory response, and reduce glomerular hypertension and fibrosis. Multiple randomized controlled trials have shown that atrasentan can effectively reduce urinary protein excretion, protect glomerular function, and significantly delay the decline of renal function in patients with diabetic nephropathy.

Atrasentan is suitable for patients with early- to mid-stage diabetic nephropathy, especially those with significant proteinuria. Long-term use of atrasentan requires comprehensive treatment measures such as blood pressure control and blood sugar management, as well as regular monitoring of renal function and electrolyte levels under the guidance of a doctor to ensure drug safety and stable efficacy.

Overall, atrasentan, as a renoprotective drug for diabetic nephropathy, is suitable for long-term management of stable disease. It can not only delay the deterioration of renal function, but also improve patients' quality of life and reduce the risk of end-stage renal disease. With the accumulation of clinical experience, the application prospects of atrasentan in the treatment of diabetic nephropathy are widely optimistic.

Reference materials:https://www.drugs.com/